Published in BMJ Open on October 25, 2013
A behavioral economic perspective on smoking persistence in serious mental illness. Prev Med (2016) 0.78
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA (2001) 17.91
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol (1999) 8.60
Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ (2008) 7.60
The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract (2005) 3.65
Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis (1999) 3.21
Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation (2000) 3.17
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis (2012) 2.39
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS (2010) 2.22
Coronary aging in HIV-infected patients. Clin Infect Dis (2009) 2.02
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions. Int J Clin Pract (2010) 1.53
Cardiovascular risk assessment for persons living with HIV. J Assoc Nurses AIDS Care (2011) 1.41
A smoking cessation programme in HIV-infected individuals: a pilot study. Antivir Ther (2006) 1.27
Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation (2008) 1.24
Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials (2010) 1.16
Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol (2011) 1.09
Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis (2012) 1.09
Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS (2007) 1.02
Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect (2008) 1.00
Life expectancy of HIV-positive adults: a review. Sex Health (2011) 1.00
A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol (2007) 0.96
Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antivir Ther (2011) 0.93
Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. J Infect (2011) 0.92
Cardiovascular risk assessment in antiretroviral-naïve HIV patients. AIDS Patient Care STDS (2009) 0.91
Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med (2004) 0.90
Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med (2003) 0.87
Comparison between the Framingham and prospective cardiovascular of Münster scores for risk assessment of coronary heart disease in human immunodeficiency virus-positive patients in Pernambuco, Brazil. Metab Syndr Relat Disord (2010) 0.87
Relations between cardiovascular risk estimates and subclinical atherosclerosis in naive HIV patients: results from the HERMES study. Int J STD AIDS (2010) 0.84
An ultrasound-based comparative study on carotid plaques in HIV-positive patients vs. atherosclerotic and arteritis patients: atherosclerotic or inflammatory lesions? Coron Artery Dis (2007) 0.82
Renal impairment is associated with coronary heart disease in HIV-positive men. HIV Clin Trials (2012) 0.81
HIV infection, aging and cardiovascular disease: epidemiology and prevention. Sex Health (2011) 0.79
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Association between birth weight and blood pressure is robust, amplifies with age, and may be underestimated. Hypertension (2006) 2.14
Late diagnosis in the HAART era: proposed common definitions and associations with mortality. AIDS (2010) 1.57
Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol (2016) 1.49
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS (2015) 1.44
HAE international home therapy consensus document. Allergy Asthma Clin Immunol (2010) 1.42
Transient loss of motor-evoked responses associated with caudal injection of morphine in a patient with spondylolisthesis undergoing spinal fusion. Paediatr Anaesth (2006) 1.39
Potentially inappropriate prescribing in older people with dementia in care homes: a retrospective analysis. Drugs Aging (2012) 1.19
The impact of CFS/ME on employment and productivity in the UK: a cross-sectional study based on the CFS/ME national outcomes database. BMC Health Serv Res (2011) 1.15
The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008. PLoS One (2011) 1.09
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS (2009) 1.09
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica (2009) 1.07
Absence of alphavbeta6 integrin is linked to initiation and progression of periodontal disease. Am J Pathol (2008) 1.01
Equity of access to specialist chronic fatigue syndrome (CFS/ME) services in England (2008-2010): a national survey and cross-sectional study. BMJ Open (2012) 1.00
Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control (2012) 1.00
A role for Rab14 in the endocytic trafficking of GLUT4 in 3T3-L1 adipocytes. J Cell Sci (2013) 0.99
Rising population cost for treating people living with HIV in the UK, 1997-2013. PLoS One (2010) 0.96
Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006. PLoS One (2011) 0.93
Overexpression of the TXNDC5 protein in non-small cell lung carcinoma. Anticancer Res (2011) 0.92
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy. AIDS (2014) 0.87
SNX15 links clathrin endocytosis to the PtdIns3P early endosome independently of the APPL1 endosome. J Cell Sci (2013) 0.86
GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours. Virchows Arch (2013) 0.85
Prenatal ethanol exposure and spatial navigation: effects of postnatal handling and aging. Dev Psychobiol (2002) 0.85
Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS (2013) 0.84
Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. AIDS (2013) 0.83
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. AIDS (2014) 0.82
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother (2013) 0.81
Virological response to initial antiretroviral regimens containing abacavir or tenofovir. J Infect Dis (2009) 0.81
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther (2011) 0.81
LYVE-1 upregulation and lymphatic invasion correlate with adverse prognostic factors and lymph node metastasis in neuroblastoma. Virchows Arch (2012) 0.80
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008. PLoS One (2012) 0.79
Effects of MHRA drug safety advice on time trends in prescribing volume and indices of clinical toxicity for quinine. Br J Clin Pharmacol (2013) 0.78
A Cross-Sectional Study on Attitudes to and Understanding of Risk of Acquisition of HIV: Design, Methods and Participant Characteristics. JMIR Res Protoc (2016) 0.78
Mathematical modelling of HIV prevention intervention. AIDS (2013) 0.78
Angiogenin up-regulation correlates with adverse clinicopathological and biological factors, increased microvascular density and poor patient outcome in neuroblastomas. Histopathology (2012) 0.77
High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas. Virchows Arch (2015) 0.75
Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS (2016) 0.75
CME Immunology and allergy (108458): self-assessment questionnaire. Clin Med (2016) 0.75
Hepatitis B, hepatitis C and mortality among HIV-positive individuals. AIDS (2017) 0.75
Impact of opioid substitution therapy on the HIV prevention benefit of antiretroviral therapy for people who inject drugs. AIDS (2017) 0.75
Podoplanin lymphatic density and invasion correlate with adverse clinicopathologic and biological factors and survival in neuroblastomas. Am J Surg Pathol (2012) 0.75
Clostridium difficile-associated colitis following the use of Chinese medicine. BMJ Case Rep (2009) 0.75
Changes in Cognitive Function Over 96 weeks in Naïve Patients Randomised to Darunavir-ritonavir plus either Raltegravir or Tenofovir-Emtricitabine: a substudy of the NEAT001/ANRS143 trial. J Acquir Immune Defic Syndr (2016) 0.75
PROX1 lymphatic density correlates with adverse clinicopathological factors, lymph node metastases and survival in neuroblastomas. J Neurooncol (2012) 0.75
Anaphylactic shock due to cefuroxime in a patient taking penicillin prophylaxis. Paediatr Anaesth (2002) 0.75